Why Endpoints is bringing a new focus to our manufacturing coverage
I’m excited to share that today we’re debuting a refresh of our manufacturing coverage here at Endpoints News.
The Covid-19 pandemic reshaped the role and prominence of manufacturing in the biopharmaceutical world, thrusting the industry into the spotlight for public and private investors, regulators and the public. And with the explosion of cell and gene therapies, the role of manufacturing — both inside companies and at contractors — has become even more crucial to the success of some of the future of biotech. With that has come increased focus from regulators, who are giving high levels of scrutiny to innovative but hard-to-make new therapies.
Starting today, Anna Brown in London will be taking over our manufacturing report that shows up in your inbox each Thursday. (If you don’t get it, you can sign up for it here.) Anna will be aided by our new London editor, Reynald Castañeda, with contributions from Lia DeGroot in Washington, as well as the senior editor for our pharma report, Zach Brennan.
All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.
This week, we’re bringing you an exclusive interview with a top executive at Lonza, coverage of the US’ efforts to ease a shortage of crucial cancer drugs, news of a major new facility in Europe and more scoops, smart analysis and breaking news. As Anna settles in, you can expect more access to conversations with the most important people in the industry as well as comprehensive coverage you need to keep track of what’s happening.
We’re always looking for story ideas, great people to interview and your feedback, so feel free to reach out to Anna by email.
Thanks for reading!